MYCN and neuroblastoma: In Stage 4 neuroblastoma patients without MYCN amplification, high TRPM2 expression correlated with worse patient event free survival compared to patients with low TRPM2 levels (Fig. 1C)40,42, suggesting that in this subgroup TRPM2 has an important role in modulating metastatic and/or refractory disease.